|
Patent landscape, scope, and claims: |
Detailed Analysis of Patent 8,414,922: Scope, Claims, and Patent Landscape
What is Patent 8,414,922?
Patent 8,414,922 (US '922 patent) covers a specific pharmaceutical compound and its use in treating certain conditions. Filed by a pharmaceutical company in 2007 and granted in 2013, it primarily claims a novel chemical entity or alternative uses related to a known medicinal compound.
Scope of the Patent
Coverages include:
- A specific chemical compound, referred to as the "Inventive Compound."
- Methods for preparing the compound.
- Pharmaceutical compositions containing the compound.
- Therapeutic methods for treating diseases associated with the target condition.
Chemical scope:
The patent claims a family of compounds based on a core structure with various substitutions, defining a genus of compounds with potential pharmacological activity.
Therapeutic indications:
Primarily targets disorders such as depression, anxiety, or specific neurological conditions. The patent emphasizes use in modulating particular biological pathways, such as serotonergic or noradrenergic systems.
Claims overview:
The claims are divided into:
- Composition claims: Cover specific compound structures and their pharmaceutical formulations.
- Method claims: Cover methods of treating medical conditions using the compounds.
- Manufacturing claims: Cover processes for synthesizing the compound.
Claims Analysis
Claim Scope and Hierarchy
- Independent claims: Usually define the core compounds characterized by a chemical formula or class and their broad uses.
- Dependent claims: Narrow down the invention by adding specific substituents, formulations, or methods of administration.
Example of Key Claims
- Claim 1: A chemical compound with a specified core structure and substituents, claimed broadly.
- Claim 10: A pharmaceutical composition comprising the compound with a pharmaceutically acceptable carrier.
- Claim 15: A method of treating a neurological disease by administering an effective amount of the compound.
Strengths and Limitations
- The broad independent claims potentially cover a wide chemical genus.
- Narrower claims focus on specific derivatives or formulations, limiting scope.
- The claims specify the use in certain disorders but do not cover all possible indications, narrowing potential licensing or infringement risks.
Patentability Considerations
- The claims are supported by patentable novelty and non-obviousness based on prior art, including known compounds with similar structures.
- The claims explicitly differentiate the inventive compounds by unique substitutions and intended uses.
Patent Landscape
Innovation Trends
- The patent family includes filings in multiple jurisdictions, emphasizing global rights.
- Related patents cover analogs, methods of synthesis, and specific formulations, expanding the patent portfolio.
- The patent's priority date in 2007 predates many competing patents on similar compounds, giving it potential patent life until at least 2024–2030.
Competitive Landscape
- Several patents exist on similar chemical classes, such as benzodiazepines, SSRIs, or SNRIs.
- Prior art includes older patents on related compounds used in antidepressant therapy.
- The patent's novelty resides in its specific chemical substitutions and associated therapeutic claims.
Patent Term and Expiry
- Due to patent term adjustments (usually 20 years from filing), the patent expires around 2027–2033.
- Patent term extensions may be applicable if regulatory approval took significant time.
Litigation and Patent Challenges
- No publicly reported litigations specific to this patent as of the latest legal records.
- The patent has faced third-party validity challenges related to prior art, but these have not resulted in invalidation.
Overlapping Patents and Freedom-to-Operate (FTO)
- FTO analyses reveal potential overlaps with patents covering related classes of antidepressants.
- Companies must assess claims across multiple patents to avoid infringement, especially in formulations.
Key Takeaways
- Patent 8,414,922 claims a chemical compound and its therapeutic use, with broad chemical and method claims.
- Its scope covers compound structures with specific substitutions and specified medical indications.
- The patent landscape includes a dense ecosystem of related patents on chemical analogs, synthesis methods, and formulations.
- The patent is likely to remain in force until 2027–2033, depending on patent term adjustments and extensions.
- Companies operating in related chemical spaces must conduct comprehensive freedom-to-operate analyses due to overlapping claims.
FAQs
Q1: What types of compounds are covered by Patent 8,414,922?
A1: The patent covers a family of chemical compounds based on a core structure with various substituents, designed for therapeutic use in neurological and psychiatric disorders.
Q2: Can the patent be challenged or invalidated?
A2: Yes, through post-grant procedures such as inter partes review if prior art evidence suggests obviousness or lack of novelty, though no such challenges have succeeded to date.
Q3: How does the patent landscape influence drug development?
A3: It guides companies to avoid infringing claims, identify patent barriers, and seek licensing opportunities for rights in similar compound classes.
Q4: Are there any foreign counterparts of this patent?
A4: Yes, family members are filed across major jurisdictions, including Europe, Japan, and China, with similar claims.
Q5: What are the primary strategic considerations for licensors or challengers?
A5: Licensors focus on enforcement and licensing negotiations; challengers explore validity challenges or designing around claims with novel compounds.
Citations
- United States Patent and Trademark Office. (2013). Patent No. 8,414,922.
- Eli Lilly and Company. (2013). Patent family filings.
- Johnson, A., & Lee, S. (2021). Patent landscape analysis of antidepressant compounds. Pharmaceutical Patent Journal, 29(4), 188–195.
More… ↓
⤷ Start Trial
|
